Regulatory News:
Medivir AB (STO:MVIR-B) (OMX: MVIR) announced that data will be presented on the investigational protease inhibitor simeprevir for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.
Help employers find you! Check out all the jobs and post your resume.
